MiR-323a regulates ErbB3/EGFR and blocks gefitinib resistance acquisition in colorectal cancer

The rapid onset of resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) limits its clinical utility in colorectal cancer (CRC) patients, and pan-erb-b2 receptor tyrosine kinase (ErbB) treatment strategy may be the alternative solution. The aim of this study was to deve...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yuanzhou, Liang, Shunshun, Xiao, Bowen, Hu, Jingying, Pang, Yechun, Liu, Yuling, Yang, Juan, Ao, Junpin, Wei, Lin, Luo, Xiaoying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940899/
https://www.ncbi.nlm.nih.gov/pubmed/35319011
http://dx.doi.org/10.1038/s41419-022-04709-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940899/
https://www.ncbi.nlm.nih.gov/pubmed/35319011
http://dx.doi.org/10.1038/s41419-022-04709-9

Ejemplares similares